Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

PDA excluded from confidential pharmacy supervision discussions

The Pharmacists’ Defence Association (PDA) has “not been approached” about proposals to allow pharmacy technicians to supervise medicines supply, despite its role in a government stakeholder group.

C+D exclusively revealed on Wednesday (September 13) that detailed proposals for pharmacy technicians to be handed legal responsibility for supervising the supply of prescription-only medicines (POMs) have been submitted to a Department of Health (DH) programme board.

A working group, established by the UK’s four chief pharmaceutical officers, has suggested amending legislation to allow a “registered pharmacy professional” – such as a pharmacy technician – to supervise the sale and supply of pharmacy (P) medicines and POMs, according to confidential documents seen by C+D.

The group suggested that a pharmacy technician could, in the pharmacist’s absence, undertake the “supervision role” of determining when medicine supplies can go ahead and “overseeing the activities of other, non-regulated, pharmacy staff”.

PDA "concerned"

PDA chair Mark Koziol said the trade body is “concerned” by the revelations in the documents. Despite being a member of a wider stakeholder group with ties to the DH’s programme board, the PDA was not aware of such proposals, he added.

“We can confirm that we have not been approached about this suggestion,” Mr Koziol said in a statement yesterday (September 14).

DH board “engagement process”

The PDA is a member of a 'partners forum', which was set up alongside the DH’s programme board in 2013 to allow wider pharmacy stakeholders to “contribute” to the board’s work on "rebalancing" medicines legislation and pharmacy regulation.

According to its terms of reference drafted at the time of the board's launch, the “engagement process the board has adopted will ensure the views of the public and patients, among others, are sought and considered effectively”.

However, Mr Koziol said there has not been a wider stakeholder group meeting “for several years”.

“The very fact that such proposals [on pharmacy supervision] could even have been drafted and were being discussed in private, without engagement from the wider profession, will have caused much concern among pharmacists,” he added.

The DH’s programme board “must increase transparency of its discussions in future, and make sure it listens to pharmacists working on the frontline”.

Pharmacy technicians' "important contribution"

The PDA said the “important contribution pharmacy technicians” make will clearly feature in any strategy for the future of the sector.

“However, [pharmacy technicians’] contribution must make pharmacists more accessible to the public…not less so, as is being advocated by the government's suggestion of remote supervision," it stressed.

“We know that a major reason why remote supervision isn’t already in place is because of widespread and consistent resistance to such proposals,” Mr Koziol added.

He called on any members who may be “concerned by this issue” to contact the PDA for support.  

Are you concerned by the pharmacy supervision proposals?

Related Content

Topics



Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now
UsernamePublicRestriction

Register

CD008944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel